Bioventix plc
("Bioventix" or "the Company")
Director Dealing
Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that the Company was notified today that on 29 January 2024 Peter Harrison, Chief Executive Officer of the Company, sold 62,000 ordinary shares of 5 pence each in the Company ("Ordinary Shares"), at a price of 4,200 pence per Ordinary Share (the "Sale").
The Sale was facilitated to enable a new institutional investor to join the share register. Peter Harrison has undertaken not to dispose of any further Ordinary Shares for 12 months.
Following the Sale, Peter Harrison has a beneficial interest in 297,088 Ordinary Shares, representing approximately 5.7 per cent. of the issued share capital of the Company.
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details.
For further information please contact:
| Bioventix plc Peter Harrison Bruce Hiscock |
Chief Executive Officer Chief Financial Officer | Tel: 01252 728 001 |
|
|
|
|
| Cavendish Capital Markets Limited Geoff Nash / Simon Hicks Nigel Birks / Harriet Ward |
Corporate Finance Corporate Broking | Tel: 020 7220 0500 |
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | Peter Harrison |
| 2. | Reason for the Notification | |
| a) | Position/status | Chief Executive Officer |
| b) | Initial notification/Amendment | Initial notification |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Bioventix plc |
| b) | LEI | 213800225MHX7LZQY108 |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the Financial instrument, type of instrument | Ordinary Shares of 5 pence each |
| Identification code | GB00B4QVDF07 | |
| b) | Nature of the transaction | Sale of Ordinary Shares |
| c) | Price(s) and volume(s) | 62,000 Ordinary Shares 4,200 pence |
| d) | Aggregated information:
· Aggregated volume
· Price | Sale of 62,000 Ordinary Shares at 4,200 pence each |
| e) | Date of the transaction | 29 January 2024 |
| f) | Place of the transaction | London Stock Exchange, AIM Market (XLON) |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.